DLocal shares are trading down Wednesday following weaker-than-expected earnings for the first quarter. The company turned in GAAP EPS of 6 cents, missing analyst estimates for EPS of 12 cents.
Benzinga Pro data, Beam Therapeutics (NASDAQ:BEAM) reported Q2 sales of $16.65 million. Earnings fell to a loss of $71.95 million, resulting in a 3.95% decrease from last quarter.